Q1 Earnings Forecast for ANRO Issued By William Blair

Alto Neuroscience, Inc. (NYSE:ANRO) – Research analysts at William Blair issued their Q1 2026 EPS estimates for Alto Neuroscience in a note issued to investors on Friday, March 21st. William Blair analyst M. Minter forecasts that the company will post earnings of ($0.53) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. William Blair also issued estimates for Alto Neuroscience’s Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.43) EPS and Q4 2026 earnings at ($0.43) EPS.

Alto Neuroscience Stock Performance

NYSE ANRO opened at $2.56 on Monday. The business’s 50-day moving average price is $3.56 and its 200 day moving average price is $5.90. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a twelve month low of $2.53 and a twelve month high of $18.35. The company has a market capitalization of $69.04 million and a PE ratio of -1.01.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.09.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ANRO. Charles Schwab Investment Management Inc. grew its holdings in Alto Neuroscience by 182.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 186,968 shares of the company’s stock valued at $2,139,000 after purchasing an additional 120,779 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Alto Neuroscience by 84.5% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 65,805 shares of the company’s stock valued at $753,000 after buying an additional 30,135 shares during the period. FMR LLC increased its holdings in shares of Alto Neuroscience by 1.4% during the 3rd quarter. FMR LLC now owns 2,363,056 shares of the company’s stock worth $27,033,000 after buying an additional 32,040 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Alto Neuroscience by 619.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock worth $49,000 after buying an additional 3,715 shares during the period. Finally, MetLife Investment Management LLC acquired a new position in Alto Neuroscience in the third quarter valued at $146,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.